Table 1.
An overview of drug/CD complexes prepared by manual grinding using mortar and pestle.
| Drug | CD 1 | Drug/CD Ratio 2 | Grinding Conditions | Properties of the Obtained Product | Reference |
|---|---|---|---|---|---|
| Chloramphenicol (mp 155.23 °C) |
β-CD | 1:1 | up to 120 min | Partial inclusion (ca. 32%) after 120 min grinding | [70] |
| Gemfibrozil (mp. 59.25 °C) |
DIMEB | 1:1 | up to 35 min | Amorphous product after 35 min grinding | [57] |
| Naproxen (mp 153.4 °C) |
βCDEPI βCDEPS |
50/50, 20/80, 15/85, 10/90 (w/w) | up to 40 min | Amorphous product with enhanced dissolution properties | [74] |
| Naproxen (mp. 153.4 °C) |
αCD maltohexaose |
0.3–0.1 (w/w) | up to 30 min | Pseudo-inclusion complex formation with maltohexaose, partial interaction with αCD | [87] |
| Trimetoprim (mp 170 °C) Sulphadiazine (mp 260.6 °C) Sulphamethoxazole (mp 201 °C) |
αCD βCD γCD RAMEB DIMEB |
1:1 | 15 min | Amorphous products with RAMEB | [88] |
| Rifaldazine (mp 259 °C) |
βCD | 1:1 | 3 min trituration followed by 30 min grinding | Amorphous product, 4.4 times higher solubility; inclusion complexation confirmed by FTIR | [56] |
| Rifampicin (mp 259 °C) |
HPβCD | 1:1 | 3 min trituration followed by 30 min grinding | Amorphous product with 2.5 times higher solubility | [58] |
1 the full name of CDs is given in the Introduction; 2 molar ratio if not otherwise stated; mp–melting point.